Short-Term Debt to Equity Ratio: Prothena Corp (PRTA)
Prothena Corporation (PRTA) is optimizing expenses by delegating clinical trials to third-party CROs to strengthen its own R&D. The use of AI in antibody modeling and plant automation is accelerating drug release, although testing remains the responsibility of physicians. The implementation of robotic manipulators in laboratories ensures 24/7 molecule screening. The stock price retrospective confirms these trends, and the current indicator is 0.01.
Prothena Corp - analytical breakdowns and key metrics (PRTA)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
- company profitability and valuation multiples indicators:
Fundamental valuation:PRTA prothena.com
Investors assess the issuer's solvency by analyzing its liability structure. The trend in short-term debt-to-equity reflects the proportion of current loans within the company's net assets. Low values confirm financial autonomy, minimizing default risk during the development of costly Parkinson's disease treatments. For Prothena Corporation (PRTA), this balance is critical, as it ensures stable funding for innovation without excessive pressure from short-term creditors.
Competitors of Prothena Corporation (PRTA)
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|denalitherapeutics.com - Current Liabilities to Equity|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|BHVN (Biohaven Ltd) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Amylyx AMLX|Trevi Corp (TRVI) - Current Liabilities to Capital|PRAX: Short-Term Debt to Equity Ratio|anavex.com - Short-Term Loans to Capital Ratio|CBLL: Short-Term Debt to Capital|Alector - Ratio of Short-Term Indebtedness to Capital|ANNX (Annexon Inc.) - Short-Term Debt to Capital|Current Liabilities to Capital Omeros Corp. OMER|Short-Term Debt to Equity Neurogene Inc. (NGNE)|acimmune.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital VYGR (Voyager Therapeutics, Inc.)|Short-Term Debt to Capital Neumora NMRA|SCLX: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital TVGN (Tevogen Bio Inc.)|ACOG: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio cogrx.com|Short-Term Debt to Equity Inhibikase Therapeutics, Inc.|Current Liabilities to Capital Cassava Sciences Inc SAVA|Short-Term Debt to Equity Assertio Holdings, Inc. (ASRT)|COYA (coyatherapeutics.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Vistagen VTGN|OVID (Ovid Therapeutics Inc) - Current Liabilities to Equity|ABOS - Short-Term Debt to Equity|Current Liabilities to Capital CervoMed, Inc.|alteritytherapeutics.com (ATHE) - Short-Term Debt to Equity|Clene - Ratio of Short-Term Indebtedness to Capital|PEPG (PepGen Inc) - Short-Term Debt to Capital|Short-Term Debt to Capital jupiterneurosciences.com|Short-Term Debt to Equity Ratio RLMD (Relmada Therapeutics, Inc.)|Short-Term Loans to Capital Ratio ANVS|Short-Term Debt to Capital GRCE (Grace Therapeutics)|Short-Term Debt to Capital Coefficient Firefly Neuro (AIFF)|KLTO - Short-Term Debt to Equity|Current Liabilities to Capital NeuroSense Therapeutics|Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio MTVA|Short-Term Debt to Equity NeurAxis, Inc|Helius Medical Technologies Inc. - Current Liabilities to Equity|Short-Term Debt to Equity Passage Bio, Inc. (PASG)|NEUP (bionomics.com.au) - Ratio of Short-Term Indebtedness to Capital|Minerva Neurosciences, Inc. - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio ATHA (Athira Pharma Inc)|Addex Therapeutics, Ltd. - Short-Term Debt to Capital|ALZN - Short-Term Debt to Capital|cyclerion.com (CYCN) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio PTIX|KTTA (Pasithea Therapeutics Corp) - Short-Term Debt to Capital|Current Liabilities to Capital Cortigent Medical CRGT|Short-Term Debt to Equity Ratio ATXI (Avenue Therapeutics, Inc)|Short-Term Debt to Capital BrainStorm Cell Therapeutics Inc. (BCLI)|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|Ratio of Short-Term Indebtedness to Capital CHRO|ELYM - Short-Term Debt to Equity|Current Liabilities to Capital Intra-Cellular Therapies|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Current Liabilities to Equity MRNS (Marinus Pharma)|Short-Term Debt to Equity NKGen Biotech, Inc.|NRBO: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Sage Therapeutics (SAGE)|SNPX - Current Liabilities to Capital|Trevena, Inc - Short-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio VIGL (Vigil Neuroscience Inc.)|Anew Medical, Inc. - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital CERE (cerevel.com)